1995
Suzhou Dawnrays Pharmaceutical Co., Ltd. was established in Suzhou, and employed elites from Pharmaceutical industry.
1998
Suzhou Dawnrays Pharmaceutical Co., Ltd. was granted the GMP certificate and became one of the first pharmaceutical companies granted the GMP certificate by the China Food and Drug Administration.
2001
According to statistics from “China Pharmaceutical Statistics Report 2001” (Pharmaceutical Chemical Section), Suzhou Dawnrays Pharmaceutical Co., Ltd. was ranked 128th and 41st among the nation's top 400 pharmaceutical enterprises in the pharmaceutical chemical section of individual entities in terms of sales income and total profit, respectively.
2002
Dawnrays Pharma invested USD 1.7 million to register as a solely foreign-invested enterprise named Suzhou Dawnrays Chemical Co., Ltd. in Wuzhong Economic Development District of Suzhou.
2003
Dawnrays Pharmaceutical (Holdings) Limited was successfully listed on the Main Board of the HKEX with stock code 02348.HK.
Suzhou Dawnrays Pharmaceutical Co., Ltd. as a core subsidiary of Dawnrays Pharma, being the first enterprise in Suzhou, as well as the first pharmaceutical enterprise in Jiangsu Province listed on the Main Board of the HKEX.
2006
Suzhou Dawnrays Chemical Co., Ltd. successfully passed the examination and attestation on three major Management Systems as conducted by American Quality Assessors International, LLC (AQA International, LLC), an accredited organization in the United States.
2007
● Dawnrays Pharma participated in the “Chinese Hypertension Intervention Efficacy Study” (CHIEF Study) under the National Science and Technology Pillar Program of China’s “Eleventh Five-year Plan” and was appointed as the designated supplier of the research drugs.
● Dawnrays (Nantong) Pharmaceutical Science and Technology Co., Ltd. held a ground-breaking ceremony in Nantong, Jiangsu Province to lay the foundation stone of its new chemical plant.
2009
Dawnrays Pharma held a ground-breaking ceremony in Hedong Industrial Park, Wuzhong Economic Development District, Suzhou to lay the foundation stone of its new plant for system specific medicines.
2010
Dawnrays Pharma boosted its sales to RMB 1.28 billion. Dawnrays Pharma divided its products into bulk drugs and finished drugs, began to optimize its product structure and enhance the ratio of finished drugs to bulk drugs.
2011
Rallyado™ (Entecavir Dispersible Tablets), an Anti-HBV medicine, was recognized as "High-tech Product of Jiangsu Province" by the Science and Technology Department of Jiangsu Province, and became the 7th High-tech product of the company.
2012
Dawnrays Pharma had entered into an agreement with GlaxoSmithKline Trading Services Limited (“GSK”), a subsidiary of GlaxoSmithKline group in respect to the supply of Entikav™ (Entecavir), a medicine for the treatment of Hepatitis B which had been registered and approved in Hong Kong and Macau, to GSK for the sales and marketing in Hong Kong and Macau.
2014
● The production workshop for Powder for Injections (cephalosporins) passed validation inspections and obtained the new Chinese GMP Certification.
● The production workshops for Sterile Bulk Medicines passed validation inspections and obtained the new Chinese GMP Certifications.
2015
● The production workshop for Powder for Injections (cephalosporins) passed validation inspections and obtained the new Chinese GMP Certification.
● The production workshops for Sterile Bulk Medicines passed validation inspections and obtained the new Chinese GMP Certifications.
2016
● Rallyado™, a generic of Entecavir Dispersible Tablets was recognized as a Famous Brand Product of Jiangsu Province by Jiangsu Provincial Brand Strategy Promotion Committee..
● Suzhou Dawnrays Pharmaceutical Co., Ltd. was honoured as one of the "Top Ten Excellent Enterprises of Jiangsu Province"..
2017
● Suzhou Dawnrays Pharmaceutical Co., Ltd. (R&D Center) was awarded one of the foreign-funded R&D centers approved in the first batch to enjoy tax rebate policy as to purchase of domestic equipment and tax policy as to import.
● Suzhou Dawnrays Pharmaceutical Co., Ltd. passed the qualification certification for“Jiangsu Provincial High-tech Enterprise”.
● Suzhou Dawnrays Pharmaceutical Co., Ltd. was awarded as“Top 100 Enterprises of China’s Chemical Pharmaceutical Industry in Integrated Corporate Strength in 2017”. The Group’s product“Amlodipine Besylate Tablet (Anneizhen)” was awarded as“Excellent Product Brand in China’s Pharmaceutical Industry in Anti-Hypertensive Class in 2017”.
● “Levamlodipine Besylate Tablet (Anmeiping)” was recognized as“High-tech Product of Jiangsu Province”.
2018
● Suzhou Dawnrays Pharmaceutical Co., Ltd. was awarded by Wuzhong District Government as “Landmark Technology (Patent) Enterprise”and “Advanced Enterprise in Energy Saving and Emission Reduction”of Wuzhong District in 2017.